| 词条 | Brecanavir |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 459812959 | IUPAC_name = [(3R,3aS,6aR)-2,3,3a,4,5,6a-Hexahydrofuro[5,4-b]furan-3-yl] N-[(2S,3R)-4-(1,3-benzodioxol-5-ylsulfonyl-(2-methylpropyl)amino)-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate | image = Brecanavir structure.svg | width = 260 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 313682-08-5 | ATC_prefix = none | ATC_suffix = | ATC_supplemental = | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 206031 | PubChem = 5743186 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = E367I8C7FI | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 4675192 | smiles = O=S(=O)(c2ccc1OCOc1c2)N(CC(C)C)C[C@@H](O)[C@@H](NC(=O)O[C@@H]3[C@@H]4CCO[C@@H]4OC3)Cc6ccc(OCc5nc(sc5)C)cc6 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C33H41N3O10S2/c1-20(2)14-36(48(39,40)25-8-9-29-30(13-25)45-19-44-29)15-28(37)27(35-33(38)46-31-17-43-32-26(31)10-11-41-32)12-22-4-6-24(7-5-22)42-16-23-18-47-21(3)34-23/h4-9,13,18,20,26-28,31-32,37H,10-12,14-17,19H2,1-3H3,(H,35,38)/t26-,27-,28+,31-,32+/m0/s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = JORVRJNILJXMMG-OLNQLETPSA-N | chemical_formula = | C=33 | H=41 | N=3 | O=10 | S=2 | molecular_weight = 703.82 }}Brecanavir (INN; codenamed GW640385) is a protease inhibitor which has been studied for the treatment of HIV.[1] On December 2006, its developer, GlaxoSmithKline discontinued further development because of insurmountable issues regarding formulation.[2] See also
References1. ^{{cite journal |vauthors=Hazen R, Harvey R, Ferris R |title=In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV |journal=Antimicrob. Agents Chemother. |volume=51 |issue=9 |pages=3147–54 |date=September 2007 |pmid=17620375 |pmc=2043237 |doi=10.1128/AAC.00401-07 |url=|display-authors=etal}} {{HIVpharm}}{{Antiinfective-agent-stub}}2. ^{{cite press release | title = GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385) | publisher = GlaxoSmithKline | date = 2006-12-18 | url = http://www.gsk.com/media/pressreleases/2006/2006_12_18_GSK945.htm | accessdate = 2008-06-11 | deadurl = yes | archiveurl = https://web.archive.org/web/20081203151032/http://www.gsk.com/media/pressreleases/2006/2006_12_18_GSK945.htm | archivedate = 2008-12-03 | df = }} 8 : Abandoned drugs|Alcohols|Benzodioxoles|Carbamates|Furofurans|HIV protease inhibitors|Phenol ethers|Thiazoles |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。